Applications: FC - Quality tested , IHC-FS - Reported in literature , IHC-PS - Reported in literature , ICC - Reported in literature , IP - Reported in literature , Activ - Reported in literature
Working Dilutions: Flow Cytometry FITC and BIOT conjugates 1 g/106 cells PE, APC, and SPRD conjugates 0.2 g/106 cells For flow cytometry, the suggested use of these reagents is in a final volume of 100 L
Probenmenge
1 mL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.5 mg/mL
Buffer
0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added
Konservierungsmittel
Without preservative
Handhabung
Each reagent is stable for the period shown on the bottle label if stored as directed.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C
Kreimann, Jang, Rong, Greite, von Vietinghoff, Schmitt, Bräsen, Schiffer, Gerstenberg, Vijayan, Dittrich-Breiholz, Wang, Karsten, Gwinner, Haller, Immenschuh, Gueler: "Ischemia Reperfusion Injury Triggers CXCL13 Release and B-Cell Recruitment After Allogenic Kidney Transplantation." in: Frontiers in immunology, Vol. 11, pp. 1204, (2020) (PubMed).
CD22, also known as Lyb-8, is a heterodimeric transmembrane glycoprotein and a member of a structurally related group of immunoglobulin (Ig) superfamily domain-containing proteins called the sialoadhesin family. It is detected in the cytoplasm early in B cell development (late pro-B cell stage), appears on the cell surface concomitant with IgD, and is found on most IgM+IgD+ mature B lymphocytes. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via cross-linking of surface Ig increases CD22 expression. CD22 associates with the B cell receptor (BCR) complex and mediates intercellular adhesion. Its intracellular domain is phosphorylated after antigen receptor cross-linking and is involved in negative regulation of B-cell activation.